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Methods: For this retrospective study, 241 imaging studies were reviewed from 1998 to 2005. Thirty-one patients met our strict diagnostic
imaging inclusion criteria and had at least 18 months of imaging follow-up. Patient demographics and lesion imaging characteristics were
tested as predictors of growth.
Results: Growth was measured over a mean period of 42 months. There was a significant (P ¼ .0004) linear growth of tumour for the
population. There was significant clustering (P ¼ .001) of the population into 2 growth rates: 0.50 mm/y (n ¼ 23) and 5.5 mm/y (n ¼ 8). The
diameter of the lesion at presentation was significantly correlated with growth (r ¼ 0.45; P ¼ .01).
Conclusion: The microcystic subtype of serous cystadenomas of the pancreas diagnosed with imaging criteria demonstrates 2 distinct and
slow growth rates. The size of the lesion at presentation is correlated with growth rate.Re´sume´Objectif: Mesurer la vitesse de croissance de l’ade´nome se´reux du pancre´as, de sous-type microkystique, diagnostique´ par imagerie.
But: Pour cette e´tude re´trospctive, 241 examens d’imagerie effectue´s de 1998 a` 2005 ont e´te´ revus. 31 patients rencontraient nos crite`res
diagnostiques rigoureux selon l’imagerie et avaient un suivi d’au moins 18 mois par imagerie. Les donne´es de´mographiques des patients et
les caracte´ristiques de la le´sion a` l’imagerie ont e´te´ e´value´s en tant que facteurs pre´dicteurs de croissance.
Re´sultas: La croissance a e´te´ mesure´e sur une pe´riode moyenne de 42 mois. On a observe´ une croissance line´aire significative (P ¼ .0004) de la
tumeur. On a note´ aussi une nette re´partition (P¼ .001) de la population e´tudie´e en deux groupes , selon la vitesse de croissance : soit un groupe a`
0.50mm/an (n ¼ 23) et l’autre a` 5.5mm/an (n ¼ 8). Le diame`tre de la le´sion a` la pre´sentation e´tait en nette relation avec la vitesse de croissance.
Conclusion: Le sous-type microkystique du cystade´nome se´reux du pancre´as diagnostique´ selon les crite`res de l’imagerie de´montre deux
formes distinctes de vitesse de croissance, chacune e´tant lente toutefois. La taille de la le´sion a` la pre´sentation est en rapport avec la vitesse de
croissance.
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doi:10.1016/j.carj.2010.04.004Increased utilisation of abdominal cross-sectional imaging
has led to increased identification of serous cystadenomas of
the pancreas [1e3]. In many instances, cystic neoplasms are
identified incidentally and are usually small at first detection
[1]. There are no explicit management, follow-up, and
treatment guidelines for small cystic tumours of the pancreasll rights reserved.
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cystic neoplasms [6, 7], whereas other investigators advocate
a more selective approach [8e11]. The overwhelming
majority of microcystic serous lesions of the pancreas are
benign adenomas, with only a handful of case reports of
serous cystadenocarcinomas [12,13]. Imaging-based diag-
nostic criteria for serous cystadenomas have been demon-
strated [14e17]. To our knowledge, only 1 previous study
attempted to characterize the growth characteristics of serous
cystadenomas [8], and none has used strict imaging diag-
nostic criteria.
The purpose of our study was to retrospectively determine
the growth rate of serous cystadenomas of the pancreas
identified by strict diagnostic imaging criteria for the
microcystic subtype, to evaluate subpopulations of growth,
and to identify predictors of growth.
Methods
Institutional ethics research review board approval was
obtained for this retrospective study; informed patient
consent was not required. We searched our patient diagnostic
imaging report database that contained data on all of the
radiologic examinations performed and reported at our
institution from January 1998 through November 2005 for
patients with a possible diagnosis of serous cystadenomas of
the pancreas (search terms: serous cystadenoma, cystic
neoplasm, pancreatic cyst, microcystic). We identified 1141
patients. A cohort of 241 patients with a minimum of 18
months imaging follow-up with computed tomography (CT)
or magnetic resonance imaging (MRI) of the pancreatic
lesions was then selected.
All of the pancreatic imaging of these 241 patients was
reviewed. Strict diagnostic imaging inclusion criteria for the
microcystic type were applied: a patient was considered to
have a serous cystadenoma if there was a cystic pancreatic
lesion that contained 6 or more cysts, all cysts were smaller
than 2 cm in size. Patients were excluded if there was
communication of the lesion with the pancreatic duct,
pancreatic-duct dilatation, or pancreatic calcifications
outside of the lesion, because these findings could also be
seen in intraductal papillary mucinous neoplasm or in
chronic pancreatitis.
A total of 31 patients (14 men, 17 women; age range, 36e
82 years; mean age, 63 years) met the selection criteria and
constituted our study population. We recorded 2 axis
measurements of the pancreatic cystic lesion size for each
imaging examination, lesion location in pancreas, enhance-
ment pattern, cystic lesion calcification pattern, and number
of cysts. The patient electronic clinical database was also
reviewed for patient demographics, presenting symptoms,
evidence of complication from pancreatic cystic lesion,
comorbidities, and living status at time of termination of the
study (November 17, 2006). The patients and/or their family
were also contacted at home if the clinical database infor-
mation was incomplete. Clinical follow-up could be
completed in 30 of 31 patients.The original cohort of 1141 patients was cross-referenced
to the operative lists. The imaging of these operated patients
was reviewed to identify patients who would have met the
imaging diagnostic criteria but would not have had long
enough imaging follow-up to be included in the study. For
any such cases, the pathology reports were reviewed.Imaging ProtocolsA variety of CT and MRI imaging protocols and equip-
ment were used during the 7-year period. Helical CTwith 4-,
8-, 16-, and 64-detector rows (GE Medical Systems, Wau-
kesha, WI; Toshiba Medical Systems, Tustin, CA; Siemens
Medical Solutions, Malvern, PA). Pancreatic CT imaging
protocols (noncontrast, followed by 45-second arterial phase
and 70e80-second portal venous phase intravenous contrast
imaging) as well as routine abdominal CT protocols (70e80-
second portal venous phase intravenous contrast imaging)
were the most commonly performed examinations. Slice-
thickness acquisition evolved during the study from 10e
2.5 mm. Abdominal MRI was performed on a 1.5 T system
(GE Medical Systems). Exact sequences varied through the
7-year period but included T2-weighted rapid acquisition
with refocused echoes (RARE) sequences in 2 planes, in-
and out-of-phase T1-weighted gradient-echo imaging, as
well as dynamic 2-dimensional and 3-dimensional T1
gradient-echo fat-saturated gadolinium-enhanced imaging.
Ultrasound examinations were performed on ATL 3500 and
5000 equipment (Philips Medical Systems, Bothwell, WA).Statistical AnalysisMeans and percentages were used as summary statistics
for continuous and categorical variables. To summarize
overall growth, a linear random effects model was fitted with
the longest lesion length as the outcome time since initial
imaging as the predictor and subject as the clustering vari-
able [18]. The investigation that there are 2 groups of growth
rates was done in 3 stages. First, a linear regression model
was fitted to each subject to estimate the subject-specific
rates of growth over time since initial imaging. Second,
these subject-specific slopes were passed to mixture model-
ling software [19] to assess whether they came from a single
population or whether they formed 2 clusters. The resulting
analysis demonstrated that the slopes came from 2 clusters.
For each slope, the probability was estimated that it came
from a specific cluster. If the estimated probability that
a subject’s slope belonged to the slow-growing cluster was
more than 50%, then a subject was classified as slow
growing; otherwise, the subject was classified as fast
growing. Comparisons of clinical and demographic charac-
teristics between slow-growing and fast-growing subjects
were made with the Fisher exact test or the 2-sample t test, as
appropriate. Individual lesion growth profiles were checked
graphically for linearity, and the fit of the mixture model to
the entire data set was assessed by computing a pseudo-R2,
the relative reduction in error variance between regression
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analyses were done in R 2.4.0 [20].
ResultPatients DemographicsA summary of patient’s demographics is presented in
Table 1. Seventeen of the 31 patients (55%) of our population
were women. Their average age was 63 years. Twenty-four
patients (77%) were still alive at the termination of the
study. None of the 7 patients who died had their cause of
death attributed to their pancreatic lesion. Eleven of the
patients (35%) had another neoplastic diagnosis.PresentationPatient demographics at first imaging of their pancreatic
serous cystadenoma are summarized in Table 1. In total, 26
of 31 patients (84%) had their pancreatic lesions identified
during imaging workup for symptoms or medical reasons
unrelated to their pancreatic lesions. These included all 11 of
the patients with other neoplastic diagnosis, 11 patients with
abdominal imaging for other illnesses, 3 patients with biliary
colic symptoms who had a pancreatic lesion incidentally
discovered on abdominal ultrasound, and 1 patient with
abdominal bloating. Five patients had symptoms that were
unexplained by original imaging (epigastric and vague
abdominal pain). All 5 of these patients had their symptomsTable 1
Patient demographics and initial presentation
No. (%)
Total no. patients 31
Sex
Men 14 (45)
Women 17 (55)
Comorbidities
Other neoplasia 11 (35)
Colon cancer 3 (10)
Breast cancer 2 (6)
Rectal cancer 2 (6)
Hepatoma 1 (3)
Lung cancer 1 (3)
Bladder TCC 1 (3)
Lymphoma 1 (3)
Diabetes mellitus type 2 4 (13)
Hepatitis B/C 3 (10)
Cause for initial imaging
Imaging of other neoplasia 11 (35)
Imaging of other comorbidity 11 (35)
Epigastric pain 4 (13)
Biliary colic 3 (10)
Vague abdominal pain 2 (6)
Bloating 1 (3)
Living status (Nov 2006)
Alive 24 (77)
Dead 7 (23)
TTC ¼ transitional cell carcinoma.resolve spontaneously in the few months after the first
imaging examination.Imaging FindingsThe imaging findings are summarized in Table 2. The
majority of the serous cystadenomas were identified in the
head of the pancreas: 14 of 31 (45%). The next most-
common location was in the tail: 8 of 31 (26%). Ninety-
four percent of lesions demonstrated septal enhancement,
whereas 6% demonstrated no enhancement. Ninety-four
percent of lesions demonstrated no signs of calcification.
The majority of lesions demonstrated greater than 9 cysts on
at least 1 imaging study: 23 of 31 (74%).Lesion GrowthThe average follow-up was 42 months (range, 20e82
months). The best regression model was a linear growth
model by using the longest measured diameter of the lesion
(pseudo-R2 ¼ 0.73). The average growth for the entire
population was 1.70 mm/y (95% confidence interval, 0.9e
2.5; P ¼ .0001). The mixture model analysis demonstrated
that the slopes were clustered into 2 different growth groups
(P ¼ .0028). The distribution of the 2 separate groups is
shown in Figure 1. The majority of patients (n ¼ 23) were in
the slower growth-rate group (mean growth rate, 0.50 mm/y;
range, 1.9e2.9 mm/y). The faster growth-rate group (mean
growth rate, 5.51 mm/y; range, 3.8e7.8 mm/y) had a smaller
number of patients (n ¼ 8). The average lesion size for the
faster growth-rate group was 4.26 cm (range, 1.7e6.8 cm;Table 2
Imaging findings
Longest diameter at presentation (cm)
Average 2.7
Range 1.3e6.2
Length of follow-up (mo)
Average 42
Range 20e82
Lesion characteristics, no. (%)
Location
Uncinate 5 (16)
Head 14 (45)
Neck 2 (6)
Body 2 (6)
Tail 8 (26)
Enhancement
Septal 29 (94)
None 2 (6)
Calcification
Septal 2 (6)
None 29 (94)
No. cysts
6e9 8 (26)
>9 23 (74)
Table 3
Predictors of growth
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2.39 cm (range, 1.3e4.0 cm; median 2.2 cm).Average growth
(mm/y) P valueaPredictors of Growth
Lesion characteristic
Enhancement
Septal (n ¼ 29) 1.73 .52
None (n ¼ 2) 2.64
Calcification
Septal (n ¼ 2) 0.70 .97
No (n ¼ 29) 1.86
No. cysts
6e9 (n ¼ 8) 1.48 .67
>9 (n ¼ 23) 1.90By using the patient’s clinical data and the imaging
findings, we investigated variables related to growth. The
analysis is summarized in Table 3. The largest diameter of
the lesion at presentation was positively correlated with
growth rate by using a Pearson correlation coefficient of 0.45
(P ¼ .01) (Figure 2). No other clinical and imaging charac-
teristics were significantly associated with growth.Largest diameter
at presentation
N/A .01P; R ¼ 0.451
Operated PatientsPatient demographics
Sex
Men (n ¼ 14) 1.54 .65
Women (n ¼ 17) 1.99
Presentation
Symptomatic (n ¼ 5) 1.78 1.00
Incidental finding (n ¼ 26) 1.80
Age N/A 0.77P; R ¼ 0.05
N/A ¼ not applicable.
aAll P values come from the Wilcoxon rank sum test, with the exception of
‘‘P,’’ which come from testing the Pearson correlation against a value of zero.In the main study cohort, 1 of 31 patients (a 39-year-old
woman), in the fast-growing group, with a lesion size of 2.5
cm, underwent a Whipple duodenopancreatectomy. The final
diagnosis was serous cystadenoma. Of the 1141 patients
whose reports were reviewed, 103 underwent surgery, with
fewer than 18 months of follow-up. None of these 103
patients met the imaging criteria for serous cystadenoma
used in this study.
Discussion
Our study demonstrates serous cystadenomas that are
defined by strict imaging criteria for the microcystic type
had slow growth rates that could be divided into 2 separate
populations. The vast majority of our studied population
had an almost negligible rate of growth, but a smaller
subset demonstrated slow linear growth. We demonstrated
a significant correlation between largest diameter atFigure 1. Comparison of growth rates of the 2 clusters. 95% confidence
interval in brackets, and mean growth are given. Individual growth rates of
each patient are represented with bars (P ¼ .0028).presentation and rate of growth. In our study, the average
growth rate of serous cystadenomas of the pancreas was
1.79 mm/y. In 2005, Tseng et al [8] established an average
growth rate for cystic pancreatic lesions that was approxi-
mately triple the growth rate in our study (6.0 mm/y). There
are a few potential explanations for this discrepancy. It isFigure 2. Correlation of growth rate and longest diameter at presentation.
Pearson covariate analysis demonstrates a significant correlation between
growth rate and longest diameter at presentation (P ¼ .001; R ¼ 0.451).
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al [8] differ in their inclusion criteria, and this could have
had a significant impact on the growth-rate assessment. The
Tseng study [8] included patients who had pathologic
diagnosis of serous cystadenomas as well as patients with
CT diagnosis consistent with serous cystadenomas or
a small indeterminate cystic lesion of the pancreas, with no
specification of the imaging criteria used. This may have
resulted in the inclusion of cystic neoplasms other than
microcystic tumours in their cohort. One might argue that,
because we studied patients with a minimum of 18 months
imaging follow-up, there was a bias towards slower-
growing tumours that would be less likely to undergo
surgery in fewer than 18 months. However, none of the
patients who met our imaging criteria were taken to surgery
during the 18-month period after initial imaging. The 1
patient who underwent surgery after a minimum of 18
months’ imaging follow-up had the expected diagnosis of
serous cystadenoma. We believe that such a bias is unlikely
to be present.Figure 3. Multiseptated cystic lesion of the tail of the pancreas in a 59-year-old w
T1 post gadolinium (B) magnetic resonance in September 1999, demonstrating
Contrast-enhanced computed tomography of March 1999 (C) and February 2005Our study population demographics was comparable with
previously published populations of serous cystadenomas;
previous average ages are reported from 61-68 years, with
a slight female predilection and a location in the uncinate,
head, and neck of the pancreas in 44%e53% [7,8,21]. The
size of tumours in our study was smaller than reported in
prior studies. The first large series of pathologically proven
serous cystadenoma was first described in 1978 [21]. This
group had an average lesion size of 10.8 cm, and 29% of the
patients were asymptomatic. In 1992, another review of
pathologically proven serous cystadenomas [7] had an
average lesion size of 6e7.5 cm, and 31% of the patients
were asymptomatic. The study by Tseng et al [8] had an
average lesion size of 4.9 cm, and 53% of all tumours were
incidentally discovered. The average lesion size in our study
is the smallest reported to date (2.7 cm). Almost all of
the lesions were identified incidentally, and 68% of the
patients had no symptoms that could be attributed to the
pancreatic lesions. The identification of smaller lesions in
asymptomatic patients may reflect the increased utilisation ofoman, demonstrating minimal growth over 71 months. T2-weighted (A) and
a multiseptated lesion in the tail of the pancreas with septal enhancement.
(D), demonstrating a minimal growth in size from 40e43 mm.
Figure 4. Multiseptated cystic lesion in the body of the pancreas in a 72-year-old woman, demonstrating significant growth over 52 months. T2-weighted
magnetic resonance image on March 1999 (A) and July 2003 (B), demonstrating growth from 37e52 mm.
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ologists and surgeons should expect in current practice.
There were some limitations in our study. Our patient
population was small, in part, secondary to our strict diag-
nostic imaging inclusion criteria and, in part, secondary to the
minimum length of imaging follow-up required to participate.
Although this raised our confidence of the studied lesions, it
has limited our statistical power and allowed us to only
identify 1 significant predictor of growth. The imaging
protocols have evolved over the 8 years of inclusion criteria.
Thinner CT slice thickness and improved MRI over the length
of the study may have improved lesion characterization, such
as assessment of the number of cysts in the lesions, and lesion
measurements. Some true serous cystadenomas may have
been excluded in the early years of the study because of poorer
image resolution and the inability to discern a sufficient
number of cysts to meet our inclusion criteria.Figure 5. Multiseptated lesion of the neck of the pancreas with septal enhancemen
Contrast-enhanced computed tomography in October 1998 (A) and May 2004 (BCystic lesions of the pancreas are increasingly identified
incidentally with increased cross-sectional imaging uti-
lisation [1]. Published recommendations for the manage-
ment of these lesions vary [1e5,10,11]. The majority of
tumours exhibit negligible growth. Those lesions that do
grow usually grow slowly (<8 mm/y). Because none of the
patients in this study had mortality associated with lesion
growth, this study supports the practice of follow-up
imaging for patients, with strict imaging criteria applied
for the diagnosis of serous cystadenoma. Further long-term
prospective studies would be required to validate this
approach and to better clarify the optimal imaging modality
and frequency. In conclusion, serous cystadenomas identi-
fied by strict diagnostic imaging criteria for the microcystic
subtype can demonstrate a negligible or a faster rate of
growth, with the size of the lesion at first presentation being
a predictor of growth.t in a 69-year-old woman, demonstrating significant growth over 67 months.
), demonstrating growth from 62e90 mm.
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